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Abstract
Background: Hypoxia inducible factor-1 alpha (HIF-1α) is a transcription factor that plays an important role in neo-
vascularisation, embryonic pancreas beta-cell mass development, and beta cell protection. Recently a non synonymous
single nucleotide polymorphism (g.C45035T SNP, rs11549465) of HIF-1α gene, resulting in the p.P582S amino acid
change has been shown to be associated with type 2 diabetes (T2DM) in a Japanese population. Our aim was to replicate
these findings on a Caucasian (Hungarian) population, as well as to study whether this genetic effect is restricted to T2DM
or can be expanded to diabetes in general.
Methods: A large Caucasian sample (N = 890) was recruited including 370 T2DM, 166 T1DM and 354 healthy subjects.
Genotyping was validated by two independent methods: a restriction fragment analysis (RFLP) and a real time PCR using
TaqMan probes. An overestimation of heterozygotes by RFLP was observed as a consequence of a nearby SNP
(rs34005929). Therefore genotyping results of the justified TaqMan system were accepted. The measured genotype
distribution corresponded to Hardy-Weinberg equilibrium (P = 0.740)
Results: As the TT genotype was extremely rare in the population (0.6% in clinical sample and 2.5% in controls), the
genotypes were grouped as T absent (CC) and T present (CT and TT). Genotype-wise analysis showed a significant
increase of T present group in controls (24.0%) as compared to patients (16.8%, P = 0.008). This genetic effect was
demonstrated in the separated samples of type 1 (15.1%, P = 0.020), and also in type 2 (17.6%, P = 0.032) diabetes. Allele-
wise analysis gave identical results showing a higher frequency of the T allele in the control sample (13.3%) than in the
clinical sample (8.7%, P = 0.002) with similar results in type 1 (7.8%, P = 0.010) and type 2 (9.1%, P = 0.011) diabetes. The
odds ratio for diabetes (either type 1 or 2) was 1.56 in the presence of the C allele.
Conclusion: We confirmed the protective effect of a rare genetic variant of HIF-1α gene against type 2 diabetes in a
Caucasian sample. Moreover we demonstrated a genetic contribution of the same polymorphism in type 1 diabetes as
well, supporting a possible overlap in pathomechanism for T2DM and a T1DM.
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Background
Type 1 (T1DM) and type 2 diabetes (T2DM) both result
from the metabolic consequences of insufficient insulin
effect, and have similar complications but appear to be
due to completely distinct pathogenetic mechanisms.
T1DM results from autoimmune β-cell destruction lead-
ing to insulin deficiency, whereas T2DM is the end point
of a progressive insulin secretory defect on a background
of insulin resistance [1].
The genetic background of both types of diabetes is unde-
niable and is being widely investigated. Both common
forms are considered to be complex diseases caused by
multiple environmental and genetic risk factors [2,3]. Pre-
viously genes such as the PPARγ, Kir6.2, Calpain-10,
TCF7L2 and class 1 HLA genes, the CTLA-4, INS, PTPN22
have been proved to be related to the manifestation of T2
and T1DM respectively [4,5]. Due to previously observed
differences in the clinical and pathogenic properties of T1
and T2DM, candidate gene studies rarely consider T2 can-
didate genes as potential T1 candidate genes and vice
versa.
Despite the clear differences between T1 and T2DM there
are indications of common etiological factors contribut-
ing to their manifestation. Investigations focusing on the
pathogenesis of β cell dysfunction in T2DM have uncov-
ered factors classically associated with T1DM. Latent
autoimmune diabetes of adults (LADA) initially has a
clinical presentation similar to T2DM and may comprise
up to 15% of the patients originally diagnosed as having
T2DM [6,7]. These patients, however, like in T1DM,
exhibit anti β cell autoimmunity and develop a progres-
sive β cell failure suggesting an overlap in etiology [8]. It
is hypothesized that an accelerated β cell loss may be the
link between T1DM and T2DM as post mortem examina-
tions of human pancreatic tissue suggest that increased
apoptosis is responsible for decreased pancreatic β cell
mass in T2DM [9]. This notion is supported by in vitro and
in vivo animal experiments, revealing apoptosis in incu-
bated rodent β cells [10] and also in cultured human islets
incubated in glucose concentrations similar to those seen
in plasma of patients with T2DM [11], and also in the
desert gerbil, during the progression to hyperglycaemia
induced by a high-energy diet [12].
This growing evidence suggests that classification of dia-
betes into two distinct diseases may not reflect the true
nature of the disorder [13]. Clearly, β cell dysfunction is a
hallmark of both types of diabetes and a genetic variant
that predisposes an individual toward reduced insulin
secretion potentially could increase the risk of developing
diabetes [14].
Hypoxia inducible factor 1 (HIF-1) is a key early mediator
of the response to ischemia. The heterodimer of HIF-1α
and β subunits is a potent transcription factor that pro-
motes cell survival, glycolysis, and angiogenesis [15]. The
transcriptional activity is primarily controlled by the oxy-
gen-regulated breakdown of the α subunit [16]. The HIF-
1α protein contains five functional domains. The basic
helix-loop-helix (bHLH) domain is specifically required
for the binding of DNA [17], the Per/Arnt/Sim (PAS)
domain is involved in dimerisation of the α and β subu-
nits. Transcriptional activation and interaction with coac-
tivators are mediated by two transactivation domains in
the C terminal half of HIF-1α, termed as N-terminal (N-
TAD) and C-terminal (C-TAD) transactivation domains
[18]. Negative regulation of HIF-1α under normoxic con-
ditions occurs via the oxygen-dependent degradation
(ODD) domain, which partly overlaps with N-
TAD.[19,20] Under normoxic conditions, HIF-1α is
hydroxylated on proline residues (P402, P564) by a fam-
ily of oxygen-dependant prolyl hydroxylases which medi-
ate high affinity binding to the von-Hippel-Landau (VHL)
protein, a component of the E3 ubiquitin-protein ligase
complex that ubiquitinates HIF-1α, thereby targeting it for
degradation[21].
The HIF-1α gene is located at chromosome 14q21-q24,
where the susceptibility locus to T2DM was localized in
Finns [22]. In a recent study Yamada and colleagues [23]
examined all regions of the HIF-1α gene in a Japanese
population and found 32 SNPs, two of them located in
exons. They found a significant association between
T2DM and a non synonymous SNP in exone 12
(rs11549465) causing a change of proline to serine
(p.P582S) in the expressed protein. Our aim was to repli-
cate Yamada's study in a diabetic sample with a different
ethnic origin, and investigate whether this genetic variant
in the HIF-1α gene, as a shared genetic contributor plays
a role in the development of not only T2DM but T1DM as
well.
Methods
Patients
Diabetic patients were recruited randomly from the inpa-
tient and outpatient services of the 2nd and 3rd Department
of Internal Medicine at the Semmelweis University. The
diagnosis of DM was based on fasting plasma glucose lev-
els or 75 g oral glucose tolerance test according to the cri-
teria of the WHO. The study was approved by the Local
Ethics Committee (TUKEB). Every patient provided writ-
ten informed consent for their participation.
The demographic variables of the samples were as follows.
T1DM sample N = 166; age: 36.9 ± 13.1; 54.8% male and
45.2% female. T2DM sample N = 370, age: 64.0 ± 12.0;
41.9% male and 58.1% female. Control subjects without
DM history were recruited at the Institute of Psychology,
Eötvös Loránd University, N = 354; age: 25.1 ± 8.5; 32.5%
male and 67.5% female. Both the clinical and the controlBMC Medical Genetics 2009, 10:79 http://www.biomedcentral.com/1471-2350/10/79
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samples were ethnically homogenous, of Caucasian ori-
gin, and consisted of unrelated individuals.
Genotyping
Non-invasive DNA sampling was applied as described
elsewhere [24]. DNA was isolated from buccal cells using
the DNA-purification kit obtained from Gentra (Minne-
apolis, US).
Restriction fragment length polymorphism
A PCR-RFLP technique developed by Percy et al. [25] was
applied with small modifications. Amplification was car-
ried out using 1 μM of each primer (forward: 5' GTG TGG
CCA TTG TAA AA 3', reverse: 5' AAC ACG TTA GGG CTT
CTT 3'), 1× buffer and Q-solution (Qiagen), 200 μM
dATP, dCTP, dGTP and dTTP, 0.1 U HotStarTaq DNA
polymerase and approximately 5 ng genomic DNA in a
final volume of 10 μL. Thermocycle: 95°C for 15 minutes,
followed by 40 cycles of 94°C, 30 sec denaturation, 52°C,
30 sec annealing and 72°C 1 min extension, with the final
polymerization at 72°C for 10 minutes.
For the genotype dependent digestion 1× NEBuffer 1, 0.1
mg/mL BSA, 0.7 U Tsp45 I restriction endonuclease (New
England Biolabs) and 5 μL PCR-product were used in a
total volume of 50 μL. Samples were incubated at 65°C
overnight and the generated DNA fragments were sepa-
rated on 1.5% agarose-2% Metaphor agarose composite
gel matrix. For controlling the complete digestion, a non-
polymorphic cleavage site was applied producing a 194-
bp-long fragment. A 260-bp-long product was observed in
case of the T allele, while a 139 bp and 121 bp fragments
were generated in the presence of the C variant.
Real-time PCR
The C__25473074_10 SNP genotyping kit obtained from
Applied Biosystems contained the two flanking primers
and the C- and T-specific probes labeled with VIC and
FAM fluorescent dyes, respectively. 1× of this genotyping
kit, 1× TaqMan® PCR Master Mix, No AmpErase® UNG and
approximately 5 ng genomic DNA was employed in a
final volume of 5 μL. A 7300 Real-Time PCR System was
used for the amplification, the first step of the thermocy-
cle was an initial denaturation and activation at 95°C for
10 minutes, followed by 40 cycles of 95°C for 15 seconds
and 60°C for 1 minute.
Comparison of the genotyping methods
150 healthy individuals were investigated using the two
independent techniques. In more than 10% of the heter-
ozygotes the Tsp45 I PCR-RFLP and the TaqMan method
gave controversial results. Direct sequencing of the PCR
products clearly demonstrated that there was a misgeno-
typing of rs11549465 SNP by PCR-RFLP. The misgenotyp-
ing was fully explained by the presence of another SNP
(rs34005929) located in a 4 bp distance thus disturbing
the correct genotyping of the studied polymorphism.
The allele discrimination of TaqMan system proved to be
reliable based on direct sequencing data. Genotypes could
be unambiguously determined on the observed ΔCT (CT
VIC - CT FAM) values. ΔCT values between -5.0 and -2.4 cor-
responded to the CC genotype, values from -1.9 to 0.7
demonstrated the heterozygote form, whereas ΔCT-s in the
range of 1.2–3.8 were characteristic to the TT variation.
Therefore the TaqMan system was used for large scale gen-
otyping. Obtained genotype frequencies were compared
to the calculated frequencies based on the Hardy-Wein-
berg equilibrium and no significant differences were
observed (P = 0.740 for all participants, P = 0.444 for the
control group, P = 0.853 for the total patient group.
Within the patient group P = 1.000 for the DM1 and P =
0.808 for the DM2 groups).
Plasmid constructs
The pGL3-Control luciferase reporter vector (Promega,
Madison, WI) was used as a control. The pHRE vector –
which is a modified pGL3-Control plasmid (figure 1A) –
containing five contiguous hypoxia responsive elements
(5'-GATCTGAGACAGCACGTAGGGC-3') in front of the
luciferase reporter gene, was a generous gift from Dr. M.
Geiszt (Institute of Physiology, Semmelweis University,
Budapest, Hungary). The wild type and p.P582S mutant
HIF-1α expression vectors were a kind gift of Dr. Yukio
Horikawa, Department of Diabetes and Endocrinology,
Gifu University School of Medicine, Gifu, Japan.
Cell cultures, hypoxic treatment, transient transfection
SK-N-FI (neuroblastoma) cell line was grown in Dul-
becco's modified Eagle's medium, high Glucose (Gibco,
Carlsbad, CA) supplemented with 10% fetal bovine
serum and 1% nonessential amino acids. Normoxic cul-
tures were kept in 21% O2, 74% N2 and 5% CO2 in
humidified atmosphere. Hypoxic samples were incubated
in a humidified atmosphere of 1% O2, 94% N2 and 5%
CO2 in a modular incubator chamber (Billups-Rothen-
berg, USA). A mixture of 0.1 μg pHRE reporter construct,
0.1 μg HIF-1α expression vector and 0.1 μg pCMV-β-gal
and 6 μl Lipofectamine 2000 (Invitrogen, Carlsbad, CA)
was used to transfect 1.2 × 106 SK-N-FI cells plated 24
hours before transfection in six-well plates. Luciferase and
β-galactosidase activities were detected using the Luci-
ferase Assay System kit (Promega, Madison, WI) and by
ONPG (O-nitrophenyl-β-D-galactopyranoside) cleavage
rate, respectively. Three parallels were used in all transfec-
tions and all experiments were performed in triplicates.
Statistical analyses
The SPSS program for Windows (13.0 version) was used
for the statistical analyses. The Hardy-Weinberg equilib-BMC Medical Genetics 2009, 10:79 http://www.biomedcentral.com/1471-2350/10/79
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rium and differences in allele and genotype distribution
of controls and patient groups (or males and females) was
tested by Chi-square analysis. Risks were examined by
odds ratios (ORs) with 95% confidence intervals (CIs),
using unconditional logistic regression models adjusted
for age (years) and sex. Possible effects of genotypes on
age or BMI were tested by t-tests. G*Power 3.1.0 [26] has
been used for computing a post hoc test for achieved
power. Input parameters included the population effect
size = 0.1 (as a conventionally small effect size), alpha =
0.05, df = 1 for our 2 × 2 and df = 2 for our 2 × 3 analyses.
Power estimates were 85% for the 2 × 2 contingency tables
and 77% for the 2 × 3 contingency tables, which are gen-
erally considered acceptable [27].
Results
DNA samples of 536 patients and 354 controls were gen-
otyped for the rs11549465 of HIF-1α gene. Considering
previous reports indicating that gender might alter glucose
homeostasis and the development of diabetes [28,29] as a
first step of analysis we excluded any possible significant
effect of sex on genotype distribution in the various study
groups. Table 1 shows the percentages of genotypes calcu-
lated for males and females, and the number of individu-
als in brackets. As the TT genotype was extremely rare in
the population, they were grouped together with CT het-
erozygotes for this analysis. Using Pearson Chi-Square test
we did not find any significant effect of sex on genotype
distribution in Controls (P = 0.379), T1DM (P = 0.435) or
in T2DM (P = 0.624) samples. Possible association of the
HIF-1α genotypes and age or BMI index has also been
tested by using the T-present vs. T-absent genotypes as
independent groups. Analyses were performed independ-
ently in the control, DM1 and DM2 groups, (data on BMI
index of controls was available for only 50 subjects). No
significant associations were found, mean age and mean
BMI of the tested T-present and T-absent genotype groups
were similar (data not shown).
The main goal of our analysis was to study the association
between the HIF-1α gene polymorphism and diabetes.
Table 2 presents the allele and genotype frequencies in the
control and the patient group as a total ("all patients"),
and in the separated groups of type 1 (T1DM) and type 2
(T2DM) diabetes. We found a statistically significant dif-
ference regarding both the genotype and allele distribu-
tion between patients and controls. Genotype-wise
analysis demonstrated a significant increase of CC
homozygotes among patients (83.2%) compared to the
controls (76%), χ2(2) = 10,792, P = 0.005. In accordance
with this, the allele-wise analysis verified a lower fre-
quency of T allele among patients (8.7%) than controls
(13.3%), χ2(1) = 9,602, P = 0.002.
Separation of diabetic patients to type 1 (T1DM) and type
2 (T2DM) gave identical results demonstrating that the
effects of HIF-1α gene variants are similar in type 1 and
type 2 diabetes (Table 2). As the T allele is relatively rare
especially among patients (8.7%), TT homozygotes do
not reach the criteria of Pearson Chi-Square test in some
cases (P values are in parentheses in Table 2). Therefore it
was necessary to group the genotype categories as T absent
(CC) and T present (CT and TT) for genotype-wise statis-
tical analysis. As it is shown in Table 2, the allele and gen-
otype distributions between type 1 and type 2 patients are
approximately equal and both groups show a statistically
significant difference if compared to the control group.
The values of significance (P) are given in Table 2 regard-
ing the comparison between the patients and the controls.
It is important to note that comparison of either allele or
genotype distribution among patients with type 1 and
type 2 diabetes did not result in any significant differ-
ences.
The presented data demonstrated an under representation
of the T allele in all patient groups suggesting a protective
effect of the T allele against diabetes. It is worth mention-
ing that -although the numbers are rather small – TT
homozygotes are extremely rare among patients (0.6%),
while their incidence is more than 4 fold higher in the
control group (2.5%). With other words, the C allele is a
risk factor for both type 1 and type 2 diabetes (OR = 1.56,
CI: 1.41–1.71). The above risk estimate was based on
unconditional logistic regression adjusted for age (years)
and sex using data from a total of 879 participants with all
data available (535 patients and 344 controls).
In order to gain more evidence for the functional role of
P582S amino acid change, transcriptional activity of the
allelic variants were compared in an in vitro reporter gene
system (see Figure 1). Five contiguous hypoxia responsive
elements (HRE) were inserted into the pGL3-Control
plasmid (pGL3-C) for the assay of HIF-1α transcriptional
activity (see Figure 1A). Two allelic forms (wt = wild type,
p.P582S = rare variant) of HIF-1α expression vector were
co-transfected with pHRE in separate experiments using
SK-N-FI (neuroblastoma) cell line. Relative HIF-1α activ-
Table 1: Distribution of Hypoxia inducible factor-1 alpha (HIF-
1α) genotypes (rs11549465) between males and females
Genotypes Male Female
Control CC 73.0% (84) 77.4% (185)
CT + TT 27.0% (31) 22.6% (54)
Type 1 Diabetes CC 86.8% (79) 82.7% (62)
CT+TT 13.2% (12) 17.3% (13)
Type 2 Diabetes CC 81.3% (126) 83.3% (179)
CT+TT 18.7% (29) 16.7% (36)BMC Medical Genetics 2009, 10:79 http://www.biomedcentral.com/1471-2350/10/79
Page 5 of 8
(page number not for citation purposes)
ity was measured in cell extracts as a ratio of luciferase
activity and the β-galactosidase activity applied as trans-
fection control. The obtained results were normalized for
the low activity of "empty" vector (pGL3-C) under nor-
moxia, and labeled on Figure 1. as relative luciferase activ-
ity. As expected, a 2–3 fold HIF-1α transcriptional activity
was measured under hypoxia (filled columns) compared
to normoxia (open columns), except in case of "empty"
vector. No significant differences were found between
allelic variants (pHRE + wt and pHRE + p.P582S) either
under normoxia or under hypoxia in our conditions. It
should be noted, however, that the endogenous HIF-1α
activity was relatively high in our system, as measured by
pHRE without cotransfection of any of the allelic variants.
Discussion
In the present genetic association analysis performed on a
Caucasian sample, we investigated the HIF-1α gene
rs11549465 SNP, a C→T non synonymous SNP
(g.C45035T) resulting in a substitution of proline to ser-
ine (P582S) in exon 12. Our result demonstrated a statis-
tically significant decrease in frequencies of T allele
containing genotypes (CT + TT), as well as in the T allele
frequencies among individuals with diabetes (see Table
2). Of note, allele and genotype distribution was very sim-
ilar between subjects with T1DM and those with T2DM.
On the other hand both the T2DM and T1DM groups
showed a statistically significant difference in allele and
genotype distribution when compared to the control. In
summary, a protective effect of the rare HIF-1α gene vari-
ant was proven against both, type 1 and type 2 diabetes,
in a Caucasian sample.
As it was pointed out by earlier studies, it is highly relevant
to replicate genetic association studies, because it is well
known that there are significant differences in the fre-
quencies of certain genetic variations among different eth-
nic groups. Our results regarding T2DM patients are in
line with the first demonstration of association between
the T allele in exon 12 of the HIF-1α gene and T2DM by
Yamada and his colleagues. The frequency of the rare T
allele in our control sample (13.3%) was comparable to
previous reports on the European population [30], and
indicated that the T allele is almost twice as frequent
among Caucasians, than observed in Yamada's Japanese
study group.
Due to the substantially different pathophysiological fea-
tures of T1 and T2DM, candidate genes of T2DM have
rarely been examined as candidate genes modifying the
risk of T1DM [31,32]. However recently an overlap has
been proposed by Wilkin and coworkers [33]. Their
"accelerator hypothesis" suggests that T1 and T2 diabetes
are the same disease of hyperglycemia-induced beta cell
damage in which T1DM has the added effect of autoim-
munity. Other findings have also strengthened this
hypothesis from a genetic point of view by demonstrating
familiar clustering of type 1 and type 2 diabetes mellitus
[34-36]. There is also evidence that for selected suscepti-
bility gene variants, there might be a shared genetic con-
tribution to the pathogenesis of T1DM and T2DM. For
example, the common variant of the peroxisome prolifer-
ator activated receptor γ gene isoform 2 (PPARγ2)
Pro12Ala that has been consistently reported to associate
with T2DM was recently shown to be associated with
Table 2: Hypoxia inducible factor-1 alpha (HIF-1α) allele and genotype frequencies in the studied groups
Genotypes CC CT TT
Control 76.0% (269) 21.5% (76) 2.5% (9)
All patients 83.2% (446) 16.2% (87) 0.6% (3) P = 0.005
T1DM 84.9% (141) 14.5% (24) 0.6% (1) P = 0.044
T2DM 82.4% (305) 17.0% (63) 0.6% (2) P = 0.023
Grouped genotypes CC CT + TT
Control 76.0% (269) 24.0% (85)
All patients 83.2% (446) 16.8% (90) P = 0.008
T1DM 84.9% (141) 15.1% (25) P = 0.020
T2DM 82.4% (305) 17.6% (65) P = 0.032
Alleles C T
Control 86.7% (614) 13.3% (94)
All patients 91.3% (979) 8.7% (93) P = 0.002
T1DM 92.2% (306) 7.8% (26) P = 0.010
T2DM 90.9% (673) 9.1% (67) P = 0.011BMC Medical Genetics 2009, 10:79 http://www.biomedcentral.com/1471-2350/10/79
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T1DM, as well [37]. Moreover, Galanakis and coworkers
just recently have shown that the intron 4 a/b polymor-
phism of the endothelial nitric oxide synthase gene
(eNOS) is associated with both type 1 and type 2 diabetes
[38]. Our new finding that indicates a decreased number
of the minor allele in the T1DM sample is another exam-
ple for the possible shared genetic background of T2 and
T1 diabetes.
The polymorphism investigated in our study causes a pro-
line to serine change in the 582 position which is within
the N-TAD near the ODD domain of the HIF-1α protein
[39]. Proline 582 has not been proven to be a HIF-1α
hydroxylation site, and it is not known whether it medi-
ates VHL binding. Moreover, the serine-proline substitu-
tion in this position does not appear to alter VHL binding
in vitro to a fragment of HIF-1α after hydroxylation at pro-
line 564 [25].
Previous in vitro functional analysis of this HIF-1α muta-
tion gave conflicting results. First Yamada and his col-
leagues [23] indicated that the mutant variant has a
consistently higher level of HIF-1α transcriptional activity
than the wild-type. Since the enhanced transactivation
capacity of the mutant was observed with statistical signif-
icance only under hypoxic condition, the authors sug-
gested that this genetic variant, by enhancing the
transcriptional activity of target genes, could be a protec-
tive factor against the onset of type 2 diabetes by its activ-
ities in the pancreatic developmental stage. Hlatky and
coworkers [30] could not replicate these findings. We also
attempted to demonstrate the functional importance of
HIF-1α variants, however, we did not find any significant
differences in the transcriptional activity of the HIF-1α
variants using a luciferase reporter system (see Figure 1).
One possible reason of this contradiction might be a rela-
tively high endogenous HIF-1α activity in our cell line as
measured in the presence of the luciferase vector with
hypoxia responsive elements (Figure 1, pHRE) in the
absence of any HIF-1α expression vector.
Tanimoto and colleagues suggested that the conforma-
tional changes caused by the amino acid substitution
either might alter protein stability, or could enhance
recruitment of transcriptional cofactors that interact with
HIF-1α. Since, the authors could not detect any differ-
ences in degradation, the altered transactivational proper-
ties was taken into consideration as a possible molecular
effect of Pro582Ser change [40]. Further investigations in
the field of cancer research demonstrated the rs11549465
variant to have enhanced transcription activities in in-vitro
studies under both normoxic and hypoxic conditions
[40,41] associated with increased tumor microvessel den-
sity in head and neck cancer, and in prostate cancer. In
conclusion, changes in the transactivational properties of
the studied genetic variants could be hypothesized, how-
ever, their effect probably depends on the specific coacti-
vators of various cell types.
HIF-1 is a major determinant in the expression and secre-
tion of vascular endothelial growth factor (VEGF) by cells
[42-44]. It has been shown that VEGF increases the sur-
vival of pancreatic islets and thus β cell sparing after islet
transplantation by stimulating angiogenesis and improv-
ing islet revascularization [45,46]. Moreover, transgenic
mice that over-express VEGF are characterized by islet
hyperplasia, suggesting that VEGF modulates endocrine
pancreatic differentiation [47]. Recent findings suggest
that VEGF protects also against the development of T1DM
and may play a role as a specific "pancreatic protector"
The effect of the p.P582S mutation on the binding affinity of  the HIF-1α to hypoxia responsive element (HRE) in SK-N-FI  cells Figure 1
The effect of the p.P582S mutation on the binding 
affinity of the HIF-1α to hypoxia responsive element 
(HRE) in SK-N-FI cells. A. Schematic description of pHRE 
vector, which is a modified pGL3-Control plasmid, containing 
five HIF-1α binding sites (HRE) in front of the SV40 pro-
moter and the luciferase reporter gene. B. No significant dif-
ference could be detected between the transcriptional 
activities of the pHRE constructs co-transfected with either 
wild type or p.P582S mutant HIF-1α, neither in normoxic 
nor under hypoxic conditions. Luciferase activity was nor-
malized to the β-galactosidase activity. Data are presented as 
fold increments over the normoxic pGL3-Control activity 
and shown as mean ± SD. Results of a representative experi-
ment are shown as measured in triplicates. Similar data were 
obtained from three independent transfection experiments.BMC Medical Genetics 2009, 10:79 http://www.biomedcentral.com/1471-2350/10/79
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[48]. Therefore, one might speculate that the studied
genetic variant of the HIF-1α, by enhancing the transcrip-
tional activity of target genes, could be a protective factor
against the onset of not only type 2 diabetes [23] but also
that of type 1 diabetes by its activities in the pancreatic
developmental stage.
Conclusion
In the presented genetic association study we determined
the genotype of the HIF-1α gene rs11549465 SNP, a C→T
non synonymous SNP (g.C45035T) resulting in a substi-
tution of proline to serine (P582S) in exon 12 on a large
Caucasian sample of diabetic patients (N = 536) and con-
trols (N = 354). In accordance with a recent study of
Yamada and colleagues [23], we found a statistically sig-
nificant decrease in frequencies of CT and TT genotypes,
as well as in the T allele frequencies among individuals
with diabetes suggesting the protective effect of the T allele
in type 2 diabetes. Moreover, the same genetic effect was
found in type 1 diabetes, as well, pinpointing the possibil-
ity of shared genetic contributors in the development of
diabetes mellitus.
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